RETATRUTIDE
US$ 28.39
ozempic semaglutide or tirzepatide vs. Semaglutide: What You Should Know Ozempic, Wegovy and Saxenda: How
Description
Retatrutide, a first-in-class GIP, GLP-1 & Glucagon triple hormone receptor agonist drug leads to nearly 29% weight loss in first pivotal test
The primary endpoint was total body weight loss percentage (TBWL%) at 12 months
GLP-1 Is Not JUST a Weight-Loss Drug
These medications make it
My GP was very direct with me: You need to lose weight, or there will be serious consequences.
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
